Upstream / Downstream
Explore pathways related to this product.
Important Ordering DetailsCustom Ordering Details: Product is assembled upon order. Please allow up to three business days for your product to be processed.
Research More. Spend Less.
Spend $650 or more and get 20% off*
(*Offer valid in the US only. Expires June 30, 2017)
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
SignalSilence® AEBP2 siRNA I #14711
This product is discontinued
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® AEBP2 siRNA I (+), or SignalSilence® AEBP2 siRNA II #14713 (+), using AEBP2 (D7C6X) Rabbit mAb #14129 (upper) and α-Actinin (D6F6) XP® Rabbit mAb #6487 (lower). The AEBP2 (D7C6X) Rabbit mAb confirms silencing of AEBP2 expression, while the α-Actinin (D6F6) XP® Rabbit mAb is used as a loading control.Learn more about how we get our images
Gallery: SignalSilence® AEBP2 siRNA I #14711
CST recommends transfection with 100 nM SignalSilence® AEBP2 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.Storage: AEBP2 siRNA I is supplied in RNAse-free water. Aliquot and store at -20ºC.
SignalSilence® AEBP2 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit AEBP2 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Polycomb group (PcG) proteins contribute to the maintenance of cell identity, stem cell self-renewal, cell cycle regulation, and oncogenesis by maintaining the silenced state of genes that promote cell lineage specification, cell death, and cell-cycle arrest (1-4). PcG proteins exist in two complexes that cooperate to maintain long-term gene silencing through epigenetic chromatin modifications. The PRC2 (EZH2-EED) complex is recruited to genes by DNA-binding transcription factors and methylates histone H3 on Lys27. Methylation of Lys27 facilitates the recruitment of the PRC1 complex, which ubiquitinylates histone H2A on Lys119 (5). Suppressor of Zeste 12 (SUZ12) is an obligate component of the PRC2 complex, which together with EZH2 and EED is absolutely required for histone methyltransferase activity of the protein complex (6).
The zinc finger AE binding protein 2 (AEBP2) is another integral component of the PRC2 complex. Addition of AEBP2 to the PRC2 core complex (EZH2-EED-SUZ12) enhances histone H3 Lys27 methyltransferase activity on nucleosomal substrates in vitro, which may be mediated in part by three AEBP2 DNA-binding zinc finger domains (5,7). AEBP2-mediated enhancement of enzymatic activity is greater on nucleosomal substrates that contain mono-ubiquitinated histone H2A Lys119, which suggests that AEBP2 may target PRC2 complexes in vivo through binding to DNA and mono-ubiquitinated histone H2A Lys119 (8).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. SignalSilence is a registered trademark of Cell Signaling Technology, Inc. XP is a registered trademark of Cell Signaling Technology, Inc.